Effects of Niacin On Fatty Acid Trapping
NCT01984073 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26
Last updated 2020-07-09
Summary
The purpose of this study is to understand whether a vitamin called NIcotinic ACid vitamIN (NIACIN for short, also known as vitamin B3) helps the body process dietary fat more efficiently. This is important because people with dyslipidemia have a problem with how they process fat, which raise the risk of heart disease.
Conditions
Interventions
- DRUG
-
ER Niacin Oral Fat Challenge
Extended release niacin 2000 mg at hour 0, followed by oral fat challenge at hour 1.
- DRUG
-
IR Niacin Oral Fat Challenge
Nialor(R) 500mg or Placebo at hour 0, 2, 4, and 6. Oral fat challenge at hour 1 (one hour after first dose of immediate-release niacin)
- OTHER
-
Placebo Oral Fat Challenge
Placebo at hour 0. Oral fat challenge at hour 1, followed by placebo at hours 2,4,and 6
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
Arizona Pharmaceuticals Inc.
collaborator INDUSTRY - lead OTHER
Principal Investigators
-
Richard L Dunbar, MD · University of Pennsylvania
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- QUADRUPLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 22 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-12-31
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
Countries
- United States
Study Locations
More Related Trials
-
Nicotinamide Riboside and Metabolic Health
NCT02835664 ·Status: COMPLETED ·Phase: NA
-
Effects of Psyllium on Niacin Tolerability
NCT03370848 ·Status: COMPLETED ·Phase: PHASE4
-
A Research Study Looking at the Effect of Food Intake on How the Medicine NN0385-0434 Behaves in the Body of Healthy Participants
NCT05091073 ·Status: COMPLETED ·Phase: PHASE1
-
Effects of Nicotinamide Riboside on Metabolism and Vascular Function
NCT03501433 ·Status: COMPLETED ·Phase: NA
-
Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy
NCT00108485 ·Status: TERMINATED ·Phase: PHASE3
-
Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia
NCT01216956 ·Status: COMPLETED ·Phase: NA
-
Niacin, N-3 Fatty Acids and Insulin Resistance
NCT00286234 ·Status: COMPLETED ·Phase: PHASE4
-
Extended Release Niacin and Fenofibrate for the Treatment of Atherogenic Dyslipidemia in Obese Females
NCT03615534 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow Reserve
NCT02969070 ·Status: COMPLETED ·Phase: NA
-
Advancing Niacin by Inhibiting Flushing (ANTI-FLUSH)
NCT00913081 ·Status: COMPLETED ·Phase: PHASE4
-
Nicotinamide Riboside and Mitochondrial Metabolism
NCT03951285 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Effects of Extended Release (ER) Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites in Subjects With High Cholesterol (0524A-075)(COMPLETED)
NCT00769132 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Nicotinic Acid on Cardiovascular Risks Indices in Polycystic Ovary Syndrome
NCT01118598 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of a Dietary Supplement on Lipid Pattern and Liver Parameters in Hypercholesterolemia
NCT04485793 ·Status: COMPLETED ·Phase: NA
-
Dyslipidemia Study Investigating The Increase In "Good Cholesterol"
NCT00169559 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312
NCT02676830 ·Status: COMPLETED ·Phase: PHASE1
-
Niacin As Secondary Prevention Of Coronary Artery Disease (NASPOCAD)
NCT00431145 ·Status: UNKNOWN ·Phase: PHASE2
-
Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19
NCT04751604 ·Status: COMPLETED ·Phase: NA
-
Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication
NCT00062556 ·Status: COMPLETED ·Phase: PHASE3
-
An Investigational Drug Study Evaluating a Novel Approach to Treat Dyslipidemia (0524A-032)
NCT00111891 ·Status: COMPLETED ·Phase: PHASE2
-
A Pilot Study to Evaluate the Lipid Effects of TRIA-662
NCT02008084 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Nicotine Acid on Dyslipidaemia in Patients With Metabolic Syndrome
NCT00659321 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)
NCT01071291 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood
NCT05979428 ·Status: COMPLETED ·Phase: PHASE1
-
Niacin/Laropiprant and Endothelial Function
NCT01126073 ·Status: COMPLETED ·Phase: PHASE4